In 2023, stakeholders identified oncologist adherence to pathways as a key priority. Before developing and launching new pathways, many payers plan to explore methods to build adherence. Discover the latest insights on oncology pathways and their impact on treatment decisions in the most recent report from NAVLIN Insights. Identify the stakeholders that have the greatest […]
Rising medical and pharmacy costs are of serious concern to regional plans who lack the financial and corporate scale of national plans. In the latest report from NAVLIN Insights, identify the strategic priorities and challenges faced by regional health plans and discover how they respond to key market trends. Gain an in-depth assessment of how […]
In the past year there has been a considerable shift in how providers and office staff value individual patient services. Understanding the distinctions in user perceptions of patient service programs is crucial for developing the targeted messages that resonate with each user type. Through this most recent report from NAVLIN Insights, gain comprehensive insights into […]
Many factors related to mental health therapies can have significant impact on brand access and patient adherence. A notable driver of patient adherence is therapy side effects. While side effects vary by product and individual patient, most payers indicate that weight gain is the side effect most cited for patient switches. Side effects impacting mental […]
Surprises and Unanswered Questions in the List of Drugs Selected for Direct Negotiations What happened? The Department of Health and Human Services (HHS) released its intended targets for Medicare price negotiations on August 29, 2023, putting affected biopharmaceutical companies on official notice for lower Medicare reimbursements in 2026 (and possible market repercussions more immediately). Need […]
Specialty Pharmacies and the Biosimilar Boom Understanding the various revenue streams of Specialty Pharmacy (SP) network partners is the key to identifying how biopharma can best incentivize SPs. A critical success factor for biosimilars is the ability to deploy unique contracting strategies that will not affect Average Sale Price (ASP). In the latest research from […]
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
